Metastatic Breast Cancer
Conditions
Keywords
Eribulin mesylate, Halaven, Breast cancer
Brief summary
The purpose of this study was to evaluate the efficacy and safety of eribulin in standard clinical practice in patients with locally recurrent or metastatic advanced breast cancer.
Detailed description
This was an observational, cross-sectional, retrospective, multicenter study conducted in Spain. During the year after authorization of the drug by the European Medicines Agency (EMA), patients in the compassionate use program (public sites) and patients treated in private sites (no purchase restrictions) who received at least 1 dose of treatment with eribulin per approved label at any of the 17 Spanish sites with the highest numbers of treated cases during that period (minimum 3 patients/site) were enrolled in this observational study. Approximately 112 patients will be enrolled in the study.
Interventions
None listed
Sponsors
Eisai Farmacêutica S.A.
Study design
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patients diagnosed with locally recurrent or metastatic advanced breast cancer, previously treated with taxanes and anthracyclines, unless these were not indicated. 2. Clinical and/or radiological documentation of location and extension of the disease at the time of starting treatment with eribulin. Patients with measurable diseases and those patients who only have non-measurable lesions are eligible. 3. Medical history documentation including analytical control data (blood count and serum chemistry including hepatic and renal functions) carried out at least one week before starting treatment with eribulin. (Determining the CA15-3 tumor marker is not indispensable). 4. Eribulin monotherapy (at least 1 dose) between April 2011 and March 2012, both inclusive. 5. Availability of a medical history allowing monitoring of clinical progression of the patients during and after treatment with eribulin.
Exclusion criteria
1. Diagnosis of any type of cancer in the last 5 years, except for non-melanoma skin cancer, cervical intraepithelial neoplasia or contralateral breast cancer. 2. Patients having received any other anti-tumor treatment, whether conventional or experimental, during the week prior to starting treatment with eribulin. Treatment with bisphosphonate and corticoids is allowed if they are clinically indicated and started 28 days before treatment with eribulin. 3. Lack of clinical status documentation after completing treatment with eribulin or, at least, after having been administered 3 initial cycles. This can arise in any of the following cases (they are not excluding): 1. Patients whose Medical History does not state the reason and date for interruption of treatment with eribulin and their subsequent clinical progression. 2. Patients still undergoing treatment with eribulin on March 31, 2012, for whom there is no data for at least the first 3 cycles.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical benefit rate | From signing of informed consent up to 1 year |
Secondary
| Measure | Time frame |
|---|---|
| Post-treatment survival | From signing of informed consent up to 1 year |
| Objective response rate | From signing of informed consent up to 1 year |
| Overall survival | From signing of informed consent up to 1 year |
| Progression-free survival | From signing of informed consent up to 1 year |
| Duration of stabilization | From signing of informed consent up to 1 year |
| Time to response from start of treatment | From signing of informed consent up to 1 year |
| Duration of response | From signing of informed consent up to 1 year |
| Progression time after interruption | From signing of informed consent up to 1 year |
| Number of patients with adverse events / serious adverse events | From signing of informed consent up to 1 year |
| Change from baseline in tumor markers CA15-3 | Baseline and up to 1 year |
Countries
Spain
Outcome results
None listed